These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31916188)

  • 1. Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition.
    Yoshinami T; Koizumi K; Nagai SE; Toyama T; Iwata H
    Breast Cancer; 2020 May; 27(3):334-339. PubMed ID: 31916188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X; Li Z; Ruan G; Tu C; Ding W
    Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
    Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
    Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.
    Zhou W; Chen S; Xu F; Zeng X
    World J Surg Oncol; 2018 Jul; 16(1):144. PubMed ID: 30007402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
    Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2015 Jun; 151(2):251-9. PubMed ID: 25917869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
    Goldvaser H; Majeed H; Ribnikar D; Šeruga B; Ocaña A; Cescon DW; Amir E
    Breast Cancer Res Treat; 2018 Jun; 169(3):413-425. PubMed ID: 29423899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
    Lambertini M; Poggio F; Bruzzone M; Conte B; Bighin C; de Azambuja E; Giuliano M; De Laurentiis M; Cognetti F; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Garrone O; Puglisi F; Montemurro F; Ceppi M; Del Mastro L;
    Int J Cancer; 2020 Jul; 147(1):160-169. PubMed ID: 31724170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.
    Nomura T; Kawai M; Fukuma Y; Koike Y; Ozaki S; Iwasaki M; Yamamoto S; Takamatsu K; Okamura H; Arai M; Ootani S; Iwata H; Saji S
    Breast Cancer; 2023 Jul; 30(4):519-530. PubMed ID: 37029889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
    Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
    Moore HC; Green SJ; Gralow JR; Bearman SI; Lew D; Barlow WE; Hudis C; Wolff AC; Ingle JN; Chew HK; Elias AD; Livingston RB; Martino S;
    J Clin Oncol; 2007 May; 25(13):1677-82. PubMed ID: 17404368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.
    Farquhar C; Marjoribanks J; Basser R; Lethaby A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003139. PubMed ID: 16034886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.
    Farquhar C; Basser R; Marjoribanks J; Lethaby A
    Cochrane Database Syst Rev; 2003; (1):CD003139. PubMed ID: 12535457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
    Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
    Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
    Lambertini M; Ceppi M; Cognetti F; Cavazzini G; De Laurentiis M; De Placido S; Michelotti A; Bisagni G; Durando A; Valle E; Scotto T; De Censi A; Turletti A; Benasso M; Barni S; Montemurro F; Puglisi F; Levaggi A; Giraudi S; Bighin C; Bruzzi P; Del Mastro L;
    Eur J Cancer; 2017 Jan; 71():34-42. PubMed ID: 27951450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes for adjuvant treatment of early breast cancer.
    Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
    Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
    Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
    Farquhar C; Basser R; Hetrick S; Lethaby A; Marjoribanks J
    Cochrane Database Syst Rev; 2003; (1):CD003142. PubMed ID: 12535458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.